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Abstract
Background Sarcopenia is an age-related muscle disease primarily characterized by reductions in muscle strength that
increases the risk of falls, fractures, cognitive impairment, and mortality. Exercise is currently preferred in prevention
and treatment, but it is unknown how different habitual physical activity and sedentary behaviour patterns associate
with sarcopenia status. The purpose of the present study was to compare associations of these patterns with probable
sarcopenia in older adults.
Methods In 3653 community-dwelling participants (51% women) aged 60–84 years from the seventh survey of the
Tromsø Study, we assessed objective physical activity and sedentary behaviour collected over 8 days (ActiGraph
wGT3X-BT Accelerometer), grip strength (Jamar+ Digital Dynamometer), five-repetition chair stands, and self-
reported disease. We combined tertiles of sedentary (SED) time and moderate-to-vigorous physical activity (MVPA)
to create nine different activity profiles (SEDHIGH, SEDMOD, and SEDLOW combined with MVPAHIGH, MVPAMOD, or
MVPALOW). Multiple logistic regression models were used to examine how these profiles associated with probable
sarcopenia, defined by low handgrip strength and/or slow chair stands time according to the revised European Working
Group on Sarcopenia in Older People criteria.
Results Probable sarcopenia was present in 227 (6.2%) participants. Men with probable sarcopenia had on average
35.3 min more SED time and 20 min less MVPA compared with participants without sarcopenia (P< 0.01 for all), while
women with probable sarcopenia only had 18 min less MVPA (P < 0.001). Compared with the SEDHIGH–MVPALOW
reference activity profile (714.2 min SED/day and 10.4 min MVPA/day), the SEDHIGH–MVPAMOD profile (697.1 min
SED/day and 31.5 min MVPA/day) had significantly lower odds ratio (OR) for probable sarcopenia (OR 0.17, 95%
confidence interval [CI] 0.08–0.35), while the SEDLOW–MVPALOW profile (482.9 min SED/day and 11.0 min
MVPA/day) did not (OR 0.72, 95% CI 0.47–1.11). These findings were not influenced by age, sex, smoking, or
self-reported diseases, and higher levels of MVPA did not further decrease ORs for probable sarcopenia.
Conclusions Older adults who achieve moderate amounts of MVPA have reduced odds for probable sarcopenia, even
when they have high sedentary time. Those with low sedentary time did not have reduced odds for probable sarcopenia
when they also had low amounts of MVPA. These findings need confirmation in longitudinal studies but suggest that
interventions for preventing sarcopenia should prioritize increasing MVPA over reducing sedentary behaviour.
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Introduction
Sarcopenia is an ICD-10-CM-categorized muscle disease that
predisposes mainly older people to falls, fractures, cognitive
impairment, and mortality.1–3 According to the revised
European Working Group on Sarcopenia in Older People
(EWGSOP2) guidelines, sarcopenia can be characterized as
probable (and interventions recommended) when an individ-
ual has reduced upper-body or lower-body muscle strength.4
This represents a shift from the earliest operational defini-
tions where sarcopenia was characterized as low muscle
mass alone.5 Similarly, the recent Sarcopenia Diagnosis
and Outcomes Consortium definition also emphasizes
muscle strength and does not recommend muscle mass
assessments.6 Regardless of the ongoing controversy over
operational definitions, the disease burden of sarcopenia is
expected to increase given ageing populations globally,7
making it a priority for researchers and policymakers to
understand how to best prevent this muscle disease.
Current evidence supports using resistance exercise as the
primary treatment to counteract sarcopenia in older adults,
as it increases both muscle strength and muscle mass.8–10
However, older adults are more likely to meet the World
Health Organization (WHO) recommendations of 150 min
of moderate-intensity aerobic physical activity per week, or
75 min of vigorous intensity per week, than to meet the
muscle-strengthening exercise recommendations of two
times per week.11 Incidental and intentional episodes of aer-
obic physical activities such as brisk walking, cycling, stair
climbing, dancing, or light running are likely common
throughout the day and could reduce the risk of incident
sarcopenia, as indicated by the AGES-Reykjavik Study using
self-reported data.12 Likewise, sedentary behaviour consti-
tutes the largest proportion of an older adult’s daily life
and has been associated with increased sarcopenia risk, indi-
cating that reduction of sedentary behaviour could be an im-
portant intervention target for sarcopenia prevention.13–15
Objective measures of daily physical activity and sedentary
behaviour patterns are becoming more readily available, min-
imizing the recall and response bias associated with
self-reported data, and allowing greater understanding of
their relationships with sarcopenia.16 Recent studies using ac-
celerometers have shown that moderate-to-vigorous physical
activity (MVPA) is associated with lower odds of prevalent
sarcopenia independent of sedentary time.13,17 However,
both these behaviours are part of a daily continuum, where in-
dividuals may have relatively high and low amounts of both
MVPA and sedentary behaviour simultaneously. Better
presentation and understanding of habitual activity and
sedentary patterns can help shape recommendations for
sarcopenia prevention and treatment. Furthermore, few stud-
ies have investigated how objective physical activity and sed-
entary behaviour are associated with both the upper-body
and lower-body strength measures that define probable
sarcopenia in the EWGSOP2 guidelines. The aim of this study
was to investigate how different activity profiles are associ-
ated with sarcopenia status based on grip strength and/or
five-repetition chair stands in a population-based sample of
older adults.
Methods
Study description and ethical approval
This cross-sectional study analysed data from the seventh
survey (Tromsø 7, 2015–2016) of the ongoing population-
based Tromsø Study in Northern Norway.18 Recruitment
and data collection procedures for Tromsø 7 have been de-
scribed previously.19,20 In short, all Tromsø inhabitants aged
40 and above (n = 32 591) were invited to a basic examina-
tion including physical examination and collection of
questionnaire data, of which 21 083 participated (65%). A
subsample (n = 9253) of these participants were also invited
to extended clinical examinations, of which 8346 (90%)
attended (Supporting Information, Figure S1). The study
was approved by the Regional Committee for Medical and
Health Research Ethics North (Ref. 2019/1136), and all
participants gave written informed consent.
Muscle strength testing
Grip strength was tested using a newly calibrated Jamar+
Digital Dynamometer (Patterson Medical, Warrenville, IL,
USA) following procedures outlined in the Southampton
protocol.21 Participants held the dynamometer in a 90°
elbow joint angle and squeezed with maximal effort. They
performed three attempts per arm, and we analysed the
highest value in kilograms from all six tries.
Lower-body muscle strength was tested using the
five-repetition chair stand test from the Short Physical Perfor-
mance Battery,22 where participants were instructed to rise
up completely five times from a chair, unaided and as fast as
possible, without stopping and keeping their arms folded
across the chest. Each participant practised one chair rise be-
fore the main test. A stopwatch was used to measure the time
in seconds between the initial seated position until the partic-
ipant stood up after the last rise. The test was aborted if more
than 60 s passed, if participants used their hands for aid, or if
there were doubts regarding the participant’s safety.
Objective physical activity data collection and
processing
Objective data on physical activity were collected using small
(4.6 × 3.3 × 1.5 cm), non-intrusive ActiGraph wGT3X-BT
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accelerometers (ActiGraph LLC, Pensacola, FL, USA) with a
sampling frequency of 100 Hz. The procedures for data
collection and processing in Tromsø 7 have been previously
described in detail.19 In short, participants wore the acceler-
ometer at their right hip for 24 h during eight consecutive
days and only removed it temporarily during water-based ac-
tivities such as showering and swimming. The accelerometer
was returned in a prepaid envelope after the measurement
period.
Raw accelerometer data were downloaded and trans-
formed into counts per minute (CPM) units by the ActiLife
software (ActiGraph LLC), whereas the custom-written Qual-
ity Control & Analysis Tool (QCAT) software was used for
wear time validation and variable generation.19 Non-wear
time protocols flagged recordings as invalid if there were
<4 days with a minimum of 10 h/day of collected data and
excluded those recordings from further analysis.23,24 The
present study used triaxial accelerometer data to capture ac-
tivity and sedentary behaviour in the three-dimensional spec-
trum, using established vector magnitude cut-points for
sedentary behaviour (<150 CPM), light physical activity
(LPA; 150–2689 CPM), and MVPA (≥2690 CPM).25,26
Covariates and sarcopenia definition
Participants answered comprehensive questionnaires includ-
ing smoking status and diseases listed as frequent underlying
causes of sarcopenia: cardiovascular disease (CVD), arthrosis,
rheumatoid arthritis, respiratory disease, diabetes, kidney
disease, and cancer.10 We used cut-points from the EWGSOP2
definition to detect sarcopenia status.4 Participants were de-
fined as having probable sarcopenia if they had low grip
strength (<16 kg for women and <27 kg for men) and/or
slow chair stands time (>15 s to perform five chair stand
repetitions for both women and men).
Statistical analyses
Descriptive data for continuous variables are presented with
means and standard deviations, with categorical variables
presented as percentages. We used the Student’s t-test to
examine differences in the continuous variables between
participants with or without probable sarcopenia and
reported mean differences with 95% confidence intervals
(CIs). For categorical variables, the χ2 test was used. We
fitted fractional polynomials and reported age-adjusted
standardized beta coefficients (β) separately for men and
women when exploring associations between physical
function and accelerometer measures.
We created tertiles of sedentary (SED) time and MVPA that
were combined into nine different activity profiles (SEDHIGH,
SEDMOD, or SEDLOW combined with MVPAHIGH, MVPAMOD, or
MVPALOW). Details regarding time in each behaviour for each
profile are outlined in Table 1. These profiles were analysed
in multiple logistic regression models with presentation of
odds ratios (ORs) and 95% CIs. For each model, SEDHIGH–
MVPALOW was used as the reference category with probable
sarcopenia as the dependent variable. Model 1 was adjusted
for age and sex. Model 2 was additionally adjusted for
smoking status and self-reported disease. We inspected the
models for multicollinearity (variance inflation factor) and
goodness of fit (Hosmer–Lemeshow), and all statistical analy-
ses were performed using Stata software Version 16.1
(StataCorp, College Station, TX, USA).
Results
From the total sample attending extended examinations
(n = 8346), we were able to include 3653 community-dwelling
older adults aged 60–84 years with complete data on objec-
tive physical activity and sedentary behaviour, upper-body
and lower-body muscle strength, self-reported smoking, and
current/previous non-communicable diseases (Figure S1).
Sensitivity analyses showed that these participants had a
slightly lower mean age, higher grip strength, and slower
chair stand times compared with a larger sample (n = 5341)
with completed physical function measures as the only
criteria (Table S1). Table 2 shows that probable sarcopenia
was prevalent in 227 out of 3653 (6.2%) participants, who
were older and more prone to be female compared with
Table 1 Description of accelerometer-based activity profiles (the Tromsø Study 2015–2016)
Activity profile N SED time/day (min) LPA/day (min) MVPA/day (min)
SEDHIGH–MVPALOW (ref group) 483 714.2 ± 66.4 343.0 ± 74.7 10.4 ± 6.1
SEDMOD–MVPALOW 417 588.6 ± 24.7 374.6 ± 85.6 10.6 ± 6.0
SEDLOW–MVPALOW 329 482.9 ± 43.4 408.0 ± 104.0 11.0 ± 5.9
SEDHIGH–MVPAMOD 428 697.1 ± 55.1 373.2 ± 68.5 31.5 ± 6.9
SEDMOD–MVPAMOD 391 587.9 ± 24.8 406.6 ± 78.9 31.3 ± 6.5
SEDLOW–MVPAMOD 390 484.6 ± 47.3 436.3 ± 90.5 31.9 ± 6.4
SEDHIGH–MVPAHIGH 306 687.4 ± 45.6 381.5 ± 66.5 67.2 ± 22.2
SEDMOD–MVPAHIGH 408 585.4 ± 24.3 405.8 ± 76.2 69.0 ± 22.2
SEDLOW–MVPAHIGH 501 477.4 ± 53.6 456.6 ± 90.5 76.7 ± 29.0
LPA, light physical activity; MOD, moderate; MVPA, moderate-to-vigorous physical activity; SED, sedentary.
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non-sarcopenic participants (both P < 0.001). There were no
significant differences in smoking status, CVD, respiratory
disease, or cancer between participants with or without
probable sarcopenia. Sarcopenic participants were more
likely to have arthrosis (51.5% vs. 24.0%), rheumatoid arthri-
tis (10.1% vs. 4.1%), diabetes (13.2% vs. 6.2%), and kidney
disease (4.0% vs. 1.6%), compared with non-sarcopenic
participants (all P < 0.05).
Men with probable sarcopenia had less LPA (27.9 min/
day, 95% CI 47.6 to 8.2) and MVPA (20.0 min/day,
95% CI 27.3 to 12.8) and higher SED time (35.3 min/day,
95% CI 11.9–58.6) compared with non-sarcopenic men
(Table 2). For women with probable sarcopenia, only physical
activity parameters differed compared with those without
sarcopenia, by 23.8 min LPA/day (95% CI 38.5 to 9.1)
and 18.0 min MVPA/day (95% CI 22.4 to 13.6). A total
of 31.3% of men and 28.6% of women with probable
sarcopenia were sufficiently physically active according to
newly proposed WHO 2020 guidelines,27 compared with
70.3% and 65.4% among non-sarcopenic men and women,
respectively (all P < 0.001). There was no difference in accel-
erometer wear time according to sarcopenia status among
men, but women with probable sarcopenia had significantly
lower wear time (3.7 h, 95% CI 6.2 to 1.1) compared
with non-sarcopenic women.
MVPA was significantly associated with grip strength in
women (β = 0.08, P = 0.001, Figure 1A) and in men
(β = 0.09, P < 0.001, Figure 1B), with a potential threshold
discernible at 15–20 min MVPA/day for both. Compared with
grip strength, the association between MVPA and chair stand
performance was stronger in both women (β = 0.26,
P < 0.001, Figure 1C) and men (β = 0.31, P < 0.001, Figure 1D),
with a threshold noticeable at 20–30 min MVPA/day. There
were no significant associations between SED time and grip
Table 2 Study sample characteristics based on sarcopenia status (the Tromsø Study 2015–2016)
Characteristic All (n = 3653) No sarcopenia (n = 3426) Probable sarcopenia (n = 227) P
Age (years) 68.5 ± 5.9 68.2 ± 5.8 72.8 ± 6.3 <0.001
Women, n (%) 1863 (51.0) 1716 (50.1) 147 (64.8) <0.001
Smoking status, n (%) 0.576
Current smoker 409 (11.2) 379 (11.1) 30 (13.2)
Previous smoker 1914 (52.4) 1800 (52.5) 114 (50.2)
CVD, previous, n (%) 365 (10.0) 337 (9.8) 28 (12.3) 0.216
Arthrosis, n (%) <0.001
Current 937 (25.7) 820 (24.0) 117 (51.5)
Previous 59 (1.6) 53 (1.6) 6 (1.6)
Rheumatoid arthritis, n (%) <0.001
Current 163 (4.5) 140 (4.1) 23 (10.1)
Previous 13 (0.4) 13 (0.4) 0 (0.0)
Respiratory disease, n (%) 0.058
Current 131 (3.6) 118 (3.4) 13 (5.7)
Previous 31 (0.9) 27 (0.8) 4 (1.8)
Diabetes, n (%) <0.001
Current 242 (6.6) 212 (6.2) 30 (13.2)
Previous 19 (0.5) 19 (0.6) 0 (0.0)
Kidney disease, n (%) 0.018
Current 62 (1.7) 53 (1.6) 9 (4.0)
Previous 95 (2.6) 91 (2.7) 4 (1.8)
Cancer, n (%) 0.148
Current 120 (3.3) 109 (3.2) 11 (4.9)
Previous 344 (9.4) 317 (9.3) 27 (11.9)
Men (n = 1790)
SED/day (min) 606.1 ± 104.3 604.5 ± 103.3 639.7 ± 119.4 0.003
LPA/day (min) 380.8 ± 87.9 382.1 ± 87.2 354.2 ± 97.7 0.006
MVPA/day (min) 41.1 ± 32.5 42.0 ± 32.5 22.0 ± 26.0 <0.001
WHO 2020 criteria, n (%)a 1227 (68.6) 1202 (70.3) 25 (31.3) <0.001
Wear time, total (h) 116.9 ± 17.1 117.0 ± 16.9 114.4 ± 20.0 0.259
Women (n = 1863)
SED/day (min) 574.4 ± 95.7 573.6 ± 95.4 583.4 ± 99.1 0.234
LPA/day (min) 415.6 ± 87.3 417.5 ± 86.3 393.7 ± 96.0 0.002
MVPA/day (min) 34.8 ± 26.6 36.2 ± 26.6 18.2 ± 20.0 <0.001
WHO 2020 criteria, n (%)a 1165 (62.5) 1123 (65.4) 42 (28.6) <0.001
Wear time, total (h) 116.6 ± 15.6 116.9 ± 15.5 113.2 ± 16.5 0.006
CVD, cardiovascular disease (myocardial infarction or stroke); LPA, light physical activity; MVPA, moderate-to-vigorous physical activity;
Respiratory disease, chronic bronchitis, emphysema, or chronic obstructive pulmonary disease; SED, sedentary; WHO, World Health
Organization.
Numbers are mean ± standard deviation or n (%). P-values indicate potential differences between no sarcopenia and probable sarcopenia
groups.
aProportions of participants achieving 150 min MVPA (non-bouted) based on the recently updatedWHO 2020 physical activity recommen-
dations for older adults.
4 J. Johansson et al.
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12718
strength in either women (Figure 2A) or men (Figure 2B), or
between SED time and chair stand performance in women
(Figure 2C). However, SED time was significantly associated
with chair stand performance in men (β = 0.08, P < 0.001,
Figure 2D).
Figure 3A shows the age-adjusted and sex-adjusted logistic
regression model examining associations between sarcopenia
status and the different activity profiles (Table 1) compared
with the SEDHIGH–MVPALOW reference (714.2 ± 66.4 min
SED/day and 10.4 ± 6.1 min MVPA/day). In this model, the
lower SED time in the SEDMOD–MVPALOW (588.6 ± 24.7 min
SED/day) and SEDLOW–MVPALOW (482.9 ± 43.4 min SED/day)
profiles did not translate to reduced odds for probable
sarcopenia (OR 0.75, 95% CI 0.50–1.13 and OR 0.72, 95% CI
Figure 1 Associations between upper/lower-body muscle strength and moderate-to-vigorous physical activity (MVPA). The Tromsø Study 2015–2016.
Data are age-adjusted fractional polynomial regression lines with 95% confidence intervals, shown for (A, C) women (red) and (B, D) men (green)
separately.
Figure 2 Associations between upper/lower-body muscle strength and sedentary (SED) time. The Tromsø Study 2015–2016. Data are age-adjusted
fractional polynomial regression lines with 95% confidence intervals, shown for (A, C) women (red) and (B, D) men (green) separately.
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0.47–1.11, respectively). The SEDHIGH–MVPAMOD profile
(697.1 ± 55.1 min SED/day and 31.5 ± 6.9 min MVPA/day)
had significantly reduced odds for probable sarcopenia (OR
0.17, 95% CI 0.08–0.35) compared with the reference profile.
Higher levels of MVPA combined with lower SED time did not
further decrease ORs for probable sarcopenia, and these
findings were not attenuated in the fully adjusted model
(Figure 3B). ORs and 95% CIs for each activity profile are
further described in Table 3.
Discussion
In this population-based study of community-dwelling older
Norwegian adults, we found that moderate amounts of
MVPA (~30 min/day) were associated with reduced odds for
probable sarcopenia even if participants also had high SED
time. Participants with low SED time and simultaneously
low amounts of MVPA (~10 min/day) did not have reduced
odds for probable sarcopenia. Furthermore, our data suggest
that achieving high amounts of MVPA (~60 min/day) may not
provide any additional benefit on upper-body and lower-body
muscle strength in older adults. These findings provide a bet-
ter understanding of how different SED and MVPA patterns
interact and associate with sarcopenia status, which could
help shape habitual activity recommendations for
prevention and treatment.
In a previous study, Sanchez-Sanchez et al. reported 15%
lower odds of sarcopenia when 15 min of SED time was re-
placed with an equal amount of MVPA and indicated a
dose–response relationship up to replacements of 60 min/
day.17 We recently also published findings on 70-year-old
Swedish adults, showing that odds for probable and con-
firmed sarcopenia were reduced by 20% per 1 h increase in
MVPA per week even after adjusting for SED time.13 The
present study expands these findings by showing that moder-
ate amounts of MVPA and high SED time can coexist during a
day while still reducing odds for probable sarcopenia. The ac-
tivity profiles included in our analyses provide a simple and
clinically interpretable overview over possible healthy and
non-healthy behaviour for sarcopenia prevention. Further-
more, these profiles lend support to previous findings based
on self-report, suggesting that MVPA may be able to
Figure 3 Multiple logistic regression models and associations between probable sarcopenia and different activity profiles. The Tromsø Study
2015–2016. Data are odds ratios with 95% confidence intervals. Odds for probable sarcopenia are compared with the different activity profiles and
the SEDHIGH–MVPALOW profile representing the reference category. (A) Model 1 is adjusted for age and sex. (B) Model 2 is further adjusted for smoking
status and self-reported diseases. MOD, moderate; MVPA, moderate-to-vigorous physical activity; SED, sedentary.
Table 3 Multiple logistic regression models and associations between probable sarcopenia and different activity profiles (the Tromsø Study
2015–2016)
Activity profile Model 1 Model 2
SEDHIGH–MVPALOW (ref) — —
SEDMOD–MVPALOW 0.75 (0.50–1.13) 0.81 (0.53–1.23)
SEDLOW–MVPALOW 0.72 (0.49–1.11) 0.75 (0.48–1.18)
SEDHIGH–MVPAMOD 0.17 (0.08–0.35) 0.18 (0.08–0.39)
SEDMOD–MVPAMOD 0.25 (0.13–0.47) 0.28 (0.15–0.54)
SEDLOW–MVPAMOD 0.33 (0.19–0.57) 0.37 (0.21–0.64)
SEDHIGH–MVPAHIGH 0.23 (0.10–0.52) 0.27 (0.12–0.60)
SEDMOD–MVPAHIGH 0.32 (0.17–0.59) 0.36 (0.20–0.68)
SEDLOW–MVPAHIGH 0.18 (0.09–0.35) 0.21 (0.11–0.41)
MOD, moderate; MVPA, moderate-to-vigorous physical activity; SED, sedentary.
Data are odds ratios with 95% confidence intervals. Odds for probable sarcopenia are compared with the different activity profiles and the
SEDHIGH–MVPALOW profile representing the reference category. Model 1 is adjusted for age and sex. Model 2 is further adjusted for
smoking status and self-reported diseases.
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‘compensate’ for the detrimental effects of sitting.28 How-
ever, the thresholds in our activity profiles are somewhat ar-
bitrary and should be interpreted as general estimates.
Dissimilar to the findings of Sanchez-Sanchez et al., we did
not see any additional benefit of higher activity or lower
SED time after participants achieved roughly 30 min of MVPA
per day. There could be several explanations for this, such as
their inclusion of older participants (mean 78 years), imple-
mentation of different accelerometer cut-offs, and use of dif-
ferent sarcopenia criteria. A recent meta-analysis on physical
activity and mortality, with similar accelerometer cut-offs and
study sample age, reported a clear saturation in the associa-
tions at 24 min MVPA/day.29 While that study investigated
a sarcopenia-related outcome and not sarcopenia directly,
and also analysed physical activity and sedentary behaviour
separately, it provides support for the potential MVPA thresh-
old found in the current study.
Similar thresholds were also discernible in the present
study when analysing how MVPA was associated with either
grip strength or chair stand performance separately. Interest-
ingly, MVPA associated more strongly with chair stand
performance compared with grip strength, potentially
driving the association between physical activity and
EWGSOP2-determined probable sarcopenia in our study.
Previous work supports these findings, showing that
accelerometer-determined physical activity associates posi-
tively with lower-limb strength but less so with grip
strength.30,31 It is plausible that hip-worn accelerometers
are able to more accurately capture activities that strengthen
the lower extremities, compared with actions that enhance
upper extremities and potentially influence grip strength
more. This emphasizes the importance of assessing
lower-body muscle strength when evaluating sarcopenia
prevention efforts involving habitual physical activity.
Resistance exercise is currently the primary recommended
treatment for sarcopenia, with documented effects on mus-
cle strength and muscle mass that rightfully position it at
the forefront.8,9,32 However, a growing body of research
indicates that promoting increased MVPA in older adults
can provide a complementary approach to sarcopenia
prevention.12,13,17 The present study supports this and addi-
tionally suggests that high amounts of sedentary behaviour,
as commonly seen in modern lifestyles, may not be deleteri-
ous as long as sufficient MVPA is achieved. Collectively, these
findings might enhance sarcopenia prevention efforts,
especially when older adults may experience several barriers
to resistance exercise maintenance and seem reluctant to
engage in specific muscle-strengthening activities.11,33
The relationship between LPA and sarcopenia is less
clear,13,17 and it is possible that low-intensity activities such
as slow walking and light household chores generate an insuf-
ficient physiological stimuli for muscle strength maintenance
among older adults. Thus, the present study primarily based
the activity profiles on MVPA, and it was also evident that
the higher LPA in the SEDLOW–MVPALOW profile compared
with the reference category did not translate to decreased
odds for probable sarcopenia. Nonetheless, it should be
noted that LPA has been shown to influence other health
outcomes, such as CVD, cognitive health, and mortality, and
contributes to the public health message ‘a little is better
than nothing’.29,34,35 The potentially complex interplay
between SED, LPA, and MVPA behaviours in preventing
sarcopenia may require more advanced statistical methods
such as compositional data analysis,36 although the output
from such analyses is more difficult to interpret and translate
into recommendations.
The current study’s main limitation is its cross-sectional
design, rendering it vulnerable to reverse causation. Thus,
it is just as likely that pre-existing muscle strength deter-
mines an individual’s physical activity and sedentary behav-
iour in our reported associations. Our conclusions should be
viewed as hypothesis generating and need confirmation in
longitudinal and experimental studies. It should be noted
that Ekelund et al. performed a similar activity profile anal-
ysis based on self-reported data and showed that physical
activity regardless of sitting time prospectively predicted
all-cause mortality.28 We used accelerometer cut-points val-
idated in a young adult population, and their applicability in
older adults is uncertain.26 However, roughly 65% of partic-
ipants achieved the newly updated WHO physical activity
recommendations of 150 min non-bouted MVPA per week,
indicating that the current cut-points were relevant for our
study sample of older adults.27 Additionally, we did not in-
clude data to investigate the successive step of confirmed
sarcopenia in the EWGSOP2 algorithm, as our previous
study indicates that a low number of participants qualified
for this criterion.37 It would be of interest to explore
whether similar associations as found in the current study
also exist for participants who additionally express low lean
mass. Nonetheless, it is clear that muscle strength is
becoming more emphasized, and lean mass less so, as
sarcopenia definitions continue to develop.4,38 Further, we
cannot rule out residual confounding in our study, as we
were unable to adjust for nutritional, drug-related, or
hospitalization-related causes of sarcopenia.10 Lastly, our re-
sults might be influenced by selection bias, as the individ-
uals declining to wear the accelerometer in Tromsø 7
were slightly older and frailer.19
Current study strengths relate to our large,
population-based study sample and to the use of objective
data on physical activity and sedentary behaviour that is less
prone to recall and response bias as seen with self-report
methods.16 We used three-dimensional accelerometer data
to capture a broad range of human movement behaviour
and thus did not restrict ourselves to simply the vertical axis,
as was common in many original accelerometer studies. We
were also able to examine associations for activity and
sedentary behaviour with both muscle strength parameters
MVPA in the Tromsø Study 2015–2016 7
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included in the EWGSOP2 definitions, compared with
previous studies that only investigated grip strength.
To conclude, older adults achieving at least moderate
amounts of MVPA have reduced odds for probable
sarcopenia, even when they have high sedentary time.
In addition, having low sedentary time was not associated
with reduced odds for probable sarcopenia if time spent in
MVPA was also low. This relationship between physical
activity patterns and sarcopenia needs confirmation in
longitudinal studies but suggests that interventions should
prioritize increasing MVPA over reducing sedentary time for
sarcopenia prevention.
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